Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6093025 | 1.00 | PTGS2 (0.83) | PTGS2PTGS1 | |
| SCHEMBL5644785 | 0.91 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL5643776 | 0.91 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL5648615 | 0.91 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL27648368 | 0.90 | PTGS2 (0.97) | PTGS2PTGS1 | |
| SCHEMBL6092055 | 0.88 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL5708951 | 0.88 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL5644640 | 0.86 | PTGS2 (0.81) | PTGS2PTGS1 | |
| SCHEMBL5647196 | 0.85 | PTGS2 (0.80) | PTGS2PTGS1 | |
| SCHEMBL5646743 | 0.84 | PTGS2 (0.78) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1725222-A2 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PSYCHIATRIC DISORDERS WITH COX-2 INHIBITORS ALONE AND IN COMBINATION WITH ANTIDEPRESSANT AGENTS | Pharmacia Corporation (US) | 2006-11-29 | — | — | EP | claimed |
| EP-1691797-A2 | COMBINATION OF CYCLOOXYGENASE-2 INHIBITOR AND PHOSPHODIESTERASE 4 INHIBITOR AND METHOD | Pharmacia Corporation (US) | 2006-08-23 | — | — | EP | claimed |
| WO-2005084654-A2 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PSYCHIATRIC DISORDERS WITH COX-2 INHIBITORS ALONE AND IN COMBINATION WITH ANTIDEPRESSANT AGENTS | PHARMACIA CORPORATION (US) | 2005-09-15 | — | — | WO | claimed |
| WO-2005049014-A1 | COX-2 INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES-RELATED OCULAR DISORDERS | PHARMACIA CORPORATION (US) | 2005-06-02 | — | — | WO | claimed |
| US-20050107349-A1 | Method for the treatment or prevention of respiratory disorders with a cyclooxygenase-2 inhibitor in combination with a muscarinic receptor antagonist and compositions therewith | PHARMACIA CORPORATION (US) | 2005-05-19 | — | — | US | claimed |
| US-20050107350-A1 | Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith | PHARMACIA CORPORATION (US) | 2005-05-19 | — | — | US | claimed |
| WO-2005041864-A2 | COMBINATION OF CYCLOOXYGENASE-2 INHIBITOR AND PHOSPHODIESTERASE 4 INHIBITOR AND METHOD | PHARMACIA CORPORATION (US) | 2005-05-12 | — | — | WO | claimed |
| US-20050049252-A1 | Substituted benzopyran derivatives for the treatment of inflammation | G.D. SEARLE & CO. (US) | 2005-03-03 | — | — | US | claimed |
| US-20040127539-A1 | Antiangiogenic combination therapy for the treatment of cancer | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | claimed |
| EP-1414526-A2 | ANTIANGIOGENIC COMBINATION THERAPY FOR THE TREATMENT OF CANCER | Pharmacia Corporation (US) | 2004-05-06 | — | — | EP | claimed |
| EP-0977748-B1 | SUBSTITUTED BENZOPYRAN DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 2003-03-26 | — | — | EP | claimed |
| WO-2002085459-A2 | ANTIANGIOGENIC COMBINATION THERAPY FOR THE TREATMENT OF CANCER | PHARMACIA CORPORATION (US) | 2002-10-31 | — | — | WO | claimed |
| US-20020103141-A1 | Antiangiogenic combination therapy for the treatment of cancer | PHARMACIA CORPORATION | 2002-08-01 | — | — | US | claimed |
| US-6034256-A | CYCLOOXYGEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2000-03-07 | — | — | US | claimed |
| EP-0977748-A1 | SUBSTITUTED BENZOPYRAN DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 2000-02-09 | — | — | EP | claimed |
| WO-1998047890-A1 | SUBSTITUTED BENZOPYRAN DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1998-10-29 | — | — | WO | claimed |
| US-7138411-B2 | Substituted benzopyran derivatives for the treatment of inflammation | G.D. SEARLE & CO. (US) | 2006-11-21 | — | — | US | disclosed |
| US-7109211-B2 | Substituted benzopyran derivatives for the treatment of inflammation | PHARMACIA CORPORATION (OF PFIZER, INC.) (US) | 2006-09-19 | — | — | US | disclosed |
| EP-0977748-A1 | SUBSTITUTED BENZOPYRAN DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 2000-02-09 | — | — | EP | disclosed |
| WO-1998047890-A1 | SUBSTITUTED BENZOPYRAN DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1998-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107349-A1 | Method for the treatment or prevention of respiratory disorders with a cyclooxygenase-2 inhibitor in combination with a muscarinic receptor antagonist and compositions therewith | CHRM3, CYSLTR2, CHRM2 | PTGS2 5/4885PTGS1 15/4885 |
| US-20050049252-A1 | Substituted benzopyran derivatives for the treatment of inflammation | PTGES2, PTGS2, PTGER2 | PTGS2 2/4885PTGS1 4/4885 |
| US-20020103141-A1 | Antiangiogenic combination therapy for the treatment of cancer | TOP2A, TOP2B, TOP1 | PTGS2 4/4885PTGS1 6/4885 |
| US-20050107350-A1 | Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith | PTGS2, PTGES2, PTGS1 | PTGS2 1/4885PTGS1 3/4885 |
| US-20040127539-A1 | Antiangiogenic combination therapy for the treatment of cancer | TOP2A, TOP2B, TOP1 | PTGS2 4/4885PTGS1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.